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ABSTRACT 
Introduct ion:  Anosmia, the loss of the sense of smell, is a rare adverse 
event associated with interferon alpha (INF-c 0. Millions of patients with hepa- 
titis B and hepatitis C virus (HCV) infection are currently treated with INF-alfa- 
2a daily. Only 5 cases of anosmia have been reported in the literature, and none 
was associated with pegylated INF-alfa. 
Case summary: A 55-year-old Arab male (height, 5'1"; weight, 81 kg) with 
chronic HCV developed anosmia and ageusia (loss of the sense of taste) after 
36 weeks of treatment for HCV with subcutaneous pegylated INF-alfa-2a 180 1Jg 
and ribavirin 1200 mg. Treatment was continued for 12 additional weeks before 
being discontinued. Twenty-four weeks after treatment was discontinued, HCV- 
RNA was undetectable and, during the same visit, the patient reported that he 
had regained his sense of smell a few weeks previously. The Naranjo algorithm 
score was 7, representing a probable association of anosmia with INF-alfa-2a 
treatment. Other etiologies for loss of smell and taste were ruled out. 
Conclusions: We report a case of anosmia and ageusia in a patient reated 
with pegylated INF-alfa-2b and ribavirin for HCV infection. The patient regained 
his sense of smell and taste within 24 weeks of stopping treatment. (Curr Ther 
Res Clin Exp. 2007;68:271-277) Copyright © 2007 Excerpta Medica, Inc. 
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INTRODUCTION 
Interferon alpha (INF-c 0 is a cytokine that has antiviral, antiproliferative, and 
immunomodulatory effects. 1 Approximately 170 million people worldwide are 
infected with hepatitis C virus (HCV) and -350 million people are infected with 
hepatitis B virus (HBV). 2 The US National Institute of Health has recommended 
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that HBV and HCV infections hould be treated with pegylated INF-alfa-2a or 
INF-alfa-2b for _>24 to 48 weeksJ INF-alfa-2a is associated with several adverse 
events (AEs), including hypothyroidism, hyperthyroidism, diabetes, psychosis, 
depression, blood dyscrasia, and various dermatologic conditions. Although 
INF-c~ has been used extensively in the treatment of HBV and HCV infections, 
only 5 cases of anosmia (loss of the sense of smell) and ageusia (loss of the 
sense of taste) associated with the use of INF-c~ have been reported in the medical 
literature. 3~ 
The aim of this study was to report a case of loss of smell and taste in a 
patient with HCV treated with pegylated INF-alfa-2a and ribavirin combination 
treatment. 
CASE SUMMARY 
A 55-year-old Arab male (height, 5'1"; weight, 81 kg) was tested at the hepatitis 
clinic of the King Khalid University Hospital, Riyadh, Saudi Arabia, in 2004 for 
chronic HCV infection. The patient's medical history included stable asthma 
and diabetes, which required occasional use of inhaled albuterol and insulin for 
-8 years, but no signs of systemic omplications (ie, chronic obstructive lung 
disease, congestive heart failure, renal failure, or psychiatric disorders). 
Physical examination was unremarkable and his vital signs (temperature, 
36.8°C; blood pressure, 112/78 mm Hg; heart rate, 81) were normal. His body 
mass index was 33 kg/m 2. Findings on examination of his eyes, ears, nose, and 
throat were within normal imits, and findings on neurologic examination were 
grossly intact. Examination of the cardiovascular system, respiratory system, 
and abdomen were normal, except for truncal obesity. The spleen was not pal- 
pable, the liver span was 12 cm, and there was no evidence of ascites or lower 
limb edema. 
Except for alanine aminotransferase (ALT) (163 U/L {normal, 10-40 U/L]), all 
laboratory tests were within normal imits, including sodium, potassium, mag- 
nesium, phosphorous, erum creatinine, blood urea nitrogen, albumin, biliru- 
bin, prothrombin time, international normalized ratio, erythrocyte sedimenta- 
tion rate, hemoglobin, and platelet count. HBV surface antigen, antismooth 
muscle antibody, and alpha-fetoprotein were all negative. The patient's liver 
biopsy was done just prior to the treatment and revealed grade III, stage III 
chronic HCV infection; HCV-RNA level was 600,000 copies/mL. 
The patient was diagnosed with chronic HCV infection and treated with sub- 
cutaneous pegylated INF-alfa-2b* 180 lJg plus ribavirin 1200 mg once a week for 
48 weeks. The treatment was well tolerated. Hemoglobin, leukocyte count, and 
platelet count were maintained within normal range and did not decrease. ALT 
activity normalized within 3 weeks and remained normal throughout he 
remainder of the treatment (week 3, 26 U/L and week 48, 33 U/L, respectively). 
*Trademark: Pegintron ® (Schering Corporation, Kenilworth, New Jersey). 
272 
A.Y. Mayet 
The remainders of the laboratory investigations were unremarkable.  After 
12 weeks of treatment, HCV-RNA, which indicates an early viral response, was 
undetectable. 
After 36 weeks of treatment, he patient noted significant hair loss from his 
beard, moustache, and scalp. He also reported fatigue, flu-like symptoms, and 
total loss of smell and taste. He reported a "stuffy nose" but did not indicate a 
history of rhinitis, exposure to chemical fumes, or head trauma. 
The patient was referred to an otolaryngologist, who found the man's mucous 
membranes,  teeth, gums, and oral cavity to be normal and without any signs of 
infection. On examination of the nose, no nasal polyps, obstruction, inflamma- 
tory process, intranasal mass, fracture of the cribriform plate, or any form of 
ulceration were noted. Neurologic examination revealed normal cranial nerve 
function without facial paralysis or facial droop. The patient was a nonsmoker. 
The patient did not complain of dry mouth, nor did he show any signs of 
Parkinson's (decrease in spontaneous movement,  gait difficulty, postural insta- 
bility, rigidity, and tremor) or Alzheimer's disease (memory  loss or behavior 
changes). Thyroid function test and vitamin levels were not determined, and he 
was not taking any medication other than pegylated INF-alfa-2b and ribavirin. 
Perfume and isopropyl alcohol smell identification tests, which are used to 
identify nerve function, were administered to the patient. He was unable to iden- 
tify either smell. Anosmia was diagnosed based on his symptoms and the results 
of the smell tests, but ageusia was noted based on the patient's complaint. 
The patient responded well to INF-alfa-2b and ribavirin; he remained on the 
regimen for 48 weeks. Twenty-four weeks after treatment was stopped, the 
patient's HCV-RNA level remained undetectable. At the same time, he reported 
that within the last several weeks he had regained his sense of smell and his 
sense of taste had improved. 
The Naranjo algorithm score 7 was 6 and 7 for ageusia nd anosmia, respectively, 
representing a probable relationship of INF-alfa-2b and ribavirin treatment. 
DISCUSSION 
Smell and taste are chemical senses that allow appreciation of the flavor of 
foods. 8 They also serve as an early warning system against oxins, polluted air, 
and smoke. Physiologically, these senses aid in normal digestion by triggering 
gastrointestinal secretions. Smell or taste dysfunction can have a significant 
impact on quality of life. Anosmia is a condition in which the sense of smell is 
reduced or lost entirely. 8 Loss of the sense of smell may be related to nasal and 
sinus disease, allergic rhinitis, chronic rhinitis, nasal polyps, adenoid hypertro- 
phy, head trauma, nasal fracture, smoking, Alzheimer's or Parkinson's disease, 
multiple sclerosis, or old age. 
Among the numerous medicat ions 9-19 (Table) that can cause loss of smell 
and taste are angiotensin-convert ing enzyme inhibitors and angiotensin- 
receptor  blockers,  fol lowed by calcium channel  blockers,  diuretics, and 
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Table. Drugs that have been associated with taste and smell disturbances. 2-12 
Amikacin Amitriptyline ACE-inhibitors 
Auranofin 13-Blockers Candesartan 
Captopril Cisplatin Clozapine 
Colchicine Corticosteroids (nasal) Doxycycline 
Diltiazem Enalapril Fluvastatin 
Gold Imipramine Interferon-c~ 
Levodopa Lithium Lovastatin 
Methimazole Methotrexate Midodrine 
Nifedipine Nortriptyline Pegylated interferon 
Phenytoin Propylthiouracil Terbinafine 
Tricyclic antidepressants Vincristine Xylocaine (nasal) 
ACE = angiotensin-converting enzyme. 
hydroxymethylglutaryl-coenzyme A. 9-11 Antiproliferative agents, such as 
5-fluorouracil, cyclophosphamide, methotrexate, cisplatin, and levamazole, can 
destroy gustatory receptors permanently while patients are taking them. 9,12,13 
Also, these antiproliferative agents and corticosteroids can alter the body's 
immune system and initiate candidal overgrowth, causing dysgeusia. 14
Antiseizure drugs (eg, phenytoin) and psychotropic agents (eg, tricyclic antide- 
pressants) can also significantly alter the taste sensation. 15
Other less common causes of anosmia and ageusia include cocaine abuse, 
toxic chemicals, and industrial agents (eg, benzene, chlorine, sulfuric acid, 
paint solvents, formaldehyde, ashes, cadmium, chromium, lead, nickel). 8Trace 
elements, such as zinc and copper, and nutritional deficiencies of vitamin A, 
vitamin B6, and vitamin B12 can also cause anosmia. 9 
At least 5 cases of INF-alfa-induced anosmia nd ageusia in patients undergo- 
ing treatment for HCV infection have been reported in the medical iterature 
(MEDLINE, OVID, and EBSCOhost; search terms: interferon, pegylated interferon, 
anosmia, loss of smell, and neurological adverse ffects). 3~ Ribavirin monothera- 
py has never been reported to cause anosmia or ageusia. 
In 2001, Manzano Alonso et al 3 reported on a patient who developed a com- 
plete loss of smell and taste while receiving INF-c¢ for chronic HCV infection. 
The 33-year-old patient had been diagnosed with HCV infection based on positive 
HCV-RNA findings and elevated ALT activity. He was treated with INF-alfa-2b 
3 million U 3 times weekly for 52 weeks. In the first month of treatment, he 
developed anosmia and ageusia. No abnormality was found on physical and 
neurologic examination, or computer tomography. However, anosmia nd ageu- 
sia persisted 18 months after treatment was discontinued. 
Fernandez Fernandez et al 4 reported that a patient receiving INF-c¢ for chronic 
HCV infection had completely lost the senses of smell and taste. 
Kraus and Vitezic 5 reported a case of INF-alfa-induced acute anosmia in a 
37-year-old patient with chronic HCV infection. The patient reported ifficulty 
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smelling after the initiation of INF-c¢ 5 million U. Within 2 weeks, the patient had 
totally lost his sense of smell. Findings on radiologic and physical examinations 
were normal, and anosmia was still present 13 months after the discontinuation 
of INF-c¢. The authors proposed that a neurotoxic mechanism ay have been 
responsible for this AE. 
Maruyama et al 6 reported that a patient with chronic active HCV infection had 
developed acute anosmia while undergoing INF-c¢ treatment. Within 10 days 
of starting daily treatment with INF-c¢ 6 million U, the patient reported ifficulty 
smelling food. Treatment was stopped after 2 months. All radiologic and physi- 
cal examination findings were normal; however, the patient showed no reaction 
to a standard olfactory acuity test. The patient had borderline diabetes, and the 
association of anosmia with impaired glucose tolerance could not be ruled out. 
However, anosmia was probably related to the INF-c¢ treatment, since it devel- 
oped 10 days after treatment was started. Nine months after discontinuation f 
INF-c¢, the anosmia had not improved. 
In 2004, Bagheri et al, 2° in their pharmacovigilance study, also had reported 
different adverse drug reactions (ADRs) while patients were receiving peginter- 
feron alfa-2b plus ribavirin for viral hepatitis during the 1-year period. Among 
them, neurosensory ADRs, including disturbances in taste, vision, hearing, or 
smell, were reported 18 times in 11 (22%) patients. 
Other rare neurologic AEs that have been reported after patients underwent 
INF-c¢ treatment are as follows: subcorticofrontal encephalopathy and choreic 
movements related to recombinant INF-alfa-2b21; refractory akathisia fter INF-c¢ 
treatment, with resting and action tremor elated to INF22; measured eclines in 
hearing, sensation, vibration, and muscle strength while patients were taking 
INF-c¢ treatment23; chronic inflammatory demyelinating polyneuropathy after 
treatment with INF-o¢24,25; Bell's palsy during INF-c¢ treatment for chronic HCV 
infection in patients with hemorrhagic disorders26; and acute sensorineural 
hearing loss associated with pegylated INF-c¢ and ribavirin combination treat- 
ment during treatment for HCV infection. 27 
The mechanism by which INF-c¢ might induce alterations in neurons and cause 
anosmia is not known; however, it may be related to changes in neuroendocrine 
hormone levels, structural similarities and common pathways between INF and 
specific neuroendocrine hormones, and the immunoregulatory effects of INE 28 
Alternatively, INF-c¢ may stimulate the manufacture of autoantibodies that damage 
the myelin sheath at peripheral neurons, resulting in permanent erve damage. 
Our patient had no known etiology for anosmia nd ageusia. It was only during 
pegylated INF-alfa-2b and ribavirin treatment that the patient developed both anos- 
mia and ageusia. He regained his senses of taste and smell when the treatment was 
stopped. It was not ethical to rechallenge the patient with INF-c¢ to reconfirm the 
AE. Of the 5 reported cases of anosmia, 3-6 2 patients developed anosmia within 
2 weeks, and in 2 other cases, anosmia remained even after INF-c¢ had been stopped 
for 9 months. Our patient regained his sense of smell 24 weeks after the comple- 
tion of 48 weeks of pegylated INF-alfa-2a treatment. 
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CONCLUSIONS 
We report a case of anosmia and ageusia in a patient treated with pegylated 
INF-alfa-2b and ribavirin for HCV infection. The patient regained his sense of 
smell and taste within 24 weeks of stopping treatment. 
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